Romero Camilo Andrés Pérez, Sánchez Isaura Pilar, Gutierrez-Hincapié Sebastian, Álvarez-Álvarez Jesús A, Pereañez Jaime Andres, Ochoa Rodrigo, Muskus-López Carlos Enrique, Eraso Ruth G, Echeverry Carolina, Arango Catalina, Restrepo José Luis Franco, Trujillo-Vargas Claudia Milena
Grupo de Inmunodeficiencias Primarias, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
J Clin Immunol. 2015 Jul;35(5):501-11. doi: 10.1007/s10875-015-0169-x. Epub 2015 May 15.
Familial Hemophagocytic Lymphohistiocytosis type 2 (FHL2) results from mutations in PRF1. We described two unrelated individuals who presented with FHL, in whom severely impaired NK cytotoxicity and decrease perforin expression was observed. DNA sequencing of PRF1 demonstrated that both were not only heterozygous for the p.54R > C/91A > V haplotype but also presented with the novel variant p.47G > V at the perforin protein. Perforin mRNA was found to be increased in a individual with that genotype. A carrier of the novel variant also demonstrated altered perforin mRNA and protein expression. Phylogenetic analysis and multiple alignments with perforin orthologous demonstrated a high level of conservation at Gly47. PolyPhen-2 and PROVEAN predicted p.47G > V to be "probably damaging" and "deleterious", respectively. A thermodynamic analysis showed that this variant was highly stabilizing, decreasing the protein internal energy. The ab initio perforin molecular modeling indicated that Gly47 is buried inside the hydrophobic core of the MACPF domain, which is crucial for the lytic pore formation and protein oligomerization. After the in silico induction of the p.47G > V mutation, Val47 increased the interactions with the surrounding amino acids due to its size and physical properties, avoiding a proper conformational change of the domain. To our knowledge, this is the first description supporting that p.47G > V is a pathogenic variant that in conjunction with p.54R > C/91A > V might result in the clinical phenotype of FHL2.
2型家族性噬血细胞性淋巴组织细胞增生症(FHL2)由PRF1基因突变引起。我们描述了两名患有FHL的无关个体,在他们身上观察到自然杀伤细胞(NK)细胞毒性严重受损以及穿孔素表达降低。PRF1的DNA测序表明,两人不仅是p.54R>C/91A>V单倍型的杂合子,而且在穿孔素蛋白上还存在新的p.47G>V变异。在一名具有该基因型的个体中发现穿孔素mRNA增加。该新变异的携带者也表现出穿孔素mRNA和蛋白表达的改变。系统发育分析以及与穿孔素直系同源物的多重比对表明,第47位甘氨酸具有高度保守性。PolyPhen-2和PROVEAN分别预测p.47G>V“可能有害”和“有害”。热力学分析表明,该变异具有高度稳定性,降低了蛋白质的内能。穿孔素的从头分子建模表明,甘氨酸47埋藏在MACPF结构域的疏水核心内,这对于裂解孔的形成和蛋白质寡聚化至关重要。在对p.47G>V突变进行计算机模拟诱导后,缬氨酸47因其大小和物理性质增加了与周围氨基酸的相互作用,从而避免了该结构域发生适当的构象变化。据我们所知,这是首次描述支持p.47G>V是一种致病变异,它与p.54R>C/91A>V一起可能导致FHL2的临床表型。